AP2408A - Pyridine[3,4-B]pyrazinones. - Google Patents

Pyridine[3,4-B]pyrazinones.

Info

Publication number
AP2408A
AP2408A AP2008004640A AP2008004640A AP2408A AP 2408 A AP2408 A AP 2408A AP 2008004640 A AP2008004640 A AP 2008004640A AP 2008004640 A AP2008004640 A AP 2008004640A AP 2408 A AP2408 A AP 2408A
Authority
AP
ARIPO
Prior art keywords
pyrazinones
pyridine
Prior art date
Application number
AP2008004640A
Other languages
English (en)
Other versions
AP2008004640A0 (en
Inventor
Andrew Simon Bell
David Louis Brown
David Graham Brown
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2008004640A0 publication Critical patent/AP2008004640A0/xx
Application granted granted Critical
Publication of AP2408A publication Critical patent/AP2408A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
AP2008004640A 2006-04-21 2007-04-10 Pyridine[3,4-B]pyrazinones. AP2408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21
PCT/IB2007/001001 WO2007122466A1 (en) 2006-04-21 2007-04-10 Pyridine[3,4-b]pyrazinones

Publications (2)

Publication Number Publication Date
AP2008004640A0 AP2008004640A0 (en) 2008-10-31
AP2408A true AP2408A (en) 2012-05-30

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004640A AP2408A (en) 2006-04-21 2007-04-10 Pyridine[3,4-B]pyrazinones.

Country Status (41)

Country Link
US (1) US7902195B2 (pl)
EP (1) EP2013208B1 (pl)
JP (1) JP4436892B2 (pl)
KR (1) KR101061328B1 (pl)
CN (1) CN101454320B (pl)
AP (1) AP2408A (pl)
AR (1) AR060525A1 (pl)
AT (1) ATE513831T1 (pl)
AU (1) AU2007242555B2 (pl)
BR (1) BRPI0710658A2 (pl)
CA (1) CA2649775C (pl)
CR (1) CR10327A (pl)
CU (1) CU23777B7 (pl)
CY (1) CY1111739T1 (pl)
DK (1) DK2013208T3 (pl)
DO (1) DOP2007000080A (pl)
EA (1) EA014919B1 (pl)
EC (1) ECSP088803A (pl)
ES (1) ES2366239T3 (pl)
GT (1) GT200700035A (pl)
HR (1) HRP20110539T1 (pl)
IL (1) IL194591A (pl)
MA (1) MA30352B1 (pl)
ME (1) MEP23808A (pl)
MX (1) MX2008012456A (pl)
MY (1) MY148583A (pl)
NL (1) NL2000583C2 (pl)
NO (1) NO20084129L (pl)
NZ (1) NZ571540A (pl)
PA (1) PA8724201A1 (pl)
PE (1) PE20080192A1 (pl)
PL (1) PL2013208T3 (pl)
RS (2) RS51885B (pl)
SI (1) SI2013208T1 (pl)
SV (1) SV2008003074A (pl)
TN (1) TNSN08408A1 (pl)
TW (1) TWI337609B (pl)
UA (1) UA92637C2 (pl)
UY (1) UY30291A1 (pl)
WO (1) WO2007122466A1 (pl)
ZA (1) ZA200808283B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI
AU2007333115B2 (en) * 2006-12-12 2013-01-10 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
PT2247292T (pt) * 2008-03-05 2017-07-17 Merck Patent Gmbh Derivados de piridopirazinonas como estimulantes da secreção de insulina, procedimentos para a sua obtenção e a sua utilização no tratamento da diabetes
TW201020233A (en) * 2008-10-09 2010-06-01 Kyorin Seiyaku Kk Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
NZ599549A (en) * 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
PT2637664T (pt) 2010-10-15 2017-06-22 Gilead Sciences Inc Composições e métodos de tratamento de hipertensão pulmonar
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
WO2014097038A1 (en) 2012-12-19 2014-06-26 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
WO2015049616A1 (en) 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
WO2015150957A1 (en) 2014-04-01 2015-10-08 Pfizer Inc. Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
AP2016009493A0 (en) 2014-04-10 2016-10-31 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
WO2016125048A1 (en) 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
ES2924371T3 (es) 2015-06-17 2022-10-06 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
BR112018015191B1 (pt) 2016-02-23 2023-10-17 Pfizer Inc Compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida, seu uso e composição farmacêutica que os compreende
DK3478679T3 (da) 2016-07-01 2021-06-21 Pfizer 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
FI3642202T3 (fi) 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
MX2019015578A (es) * 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CA3094366A1 (en) 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivatives
EP4297868A4 (en) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. USE OF APREPITANT TO TREAT ALZHEIMER'S
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
WO2025160132A1 (en) * 2024-01-23 2025-07-31 Maplight Therapeutics, Inc. Gpr6 inverse agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (en) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
AU656154B2 (en) * 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
TW274550B (pl) * 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) * 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
EP1624900A4 (en) * 2003-05-20 2007-05-02 Univ California METHOD OF BINDING AGENTS AT BETA AMYLOID PLAQUE
CA2529196A1 (en) * 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
CA2593005A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
JP2009509923A (ja) * 2005-08-26 2009-03-12 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (en) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors

Also Published As

Publication number Publication date
HRP20110539T1 (hr) 2011-08-31
TWI337609B (en) 2011-02-21
SI2013208T1 (sl) 2011-09-30
NZ571540A (en) 2010-10-29
PA8724201A1 (es) 2009-08-26
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
CA2649775C (en) 2011-05-31
NO20084129L (no) 2008-10-29
AU2007242555A1 (en) 2007-11-01
US20070249615A1 (en) 2007-10-25
ES2366239T3 (es) 2011-10-18
CN101454320A (zh) 2009-06-10
MEP23808A (en) 2010-06-10
KR101061328B1 (ko) 2011-08-31
RS51885B (sr) 2012-02-29
AR060525A1 (es) 2008-06-25
UY30291A1 (es) 2007-11-30
BRPI0710658A2 (pt) 2011-08-16
HK1133875A1 (en) 2010-04-09
NL2000583A1 (nl) 2007-10-23
DOP2007000080A (es) 2007-11-15
GT200700035A (es) 2008-02-05
JP2009534368A (ja) 2009-09-24
AU2007242555B2 (en) 2010-12-16
CU20080194A7 (es) 2011-03-21
CY1111739T1 (el) 2015-10-07
EA014919B1 (ru) 2011-04-29
TW200808794A (en) 2008-02-16
CU23777B7 (es) 2012-02-15
CR10327A (es) 2008-10-21
ATE513831T1 (de) 2011-07-15
DK2013208T3 (da) 2011-08-15
PE20080192A1 (es) 2008-03-01
RS20080484A (sr) 2009-07-15
ECSP088803A (es) 2008-11-27
PL2013208T3 (pl) 2011-10-31
EP2013208A1 (en) 2009-01-14
CA2649775A1 (en) 2007-11-01
MX2008012456A (es) 2008-10-10
EP2013208B1 (en) 2011-06-22
SV2008003074A (es) 2010-01-12
WO2007122466A1 (en) 2007-11-01
IL194591A (en) 2012-07-31
AP2008004640A0 (en) 2008-10-31
MY148583A (en) 2013-04-30
MA30352B1 (fr) 2009-04-01
EA200801998A1 (ru) 2009-04-28
KR20080110930A (ko) 2008-12-19
TNSN08408A1 (fr) 2010-04-14
ZA200808283B (en) 2009-11-25
CN101454320B (zh) 2012-12-19
JP4436892B2 (ja) 2010-03-24
US7902195B2 (en) 2011-03-08

Similar Documents

Publication Publication Date Title
AP2408A (en) Pyridine[3,4-B]pyrazinones.
IL201973A0 (en) 3,3-spiroindolinone derivatives
SI2334687T1 (sl) Dioksa biciklo oktan triol derivati
EG25264A (en) Biphenyl-n-(4-pyridyl) methylsulfonamides.
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
ZA200805354B (en) Aryl-isoxazol-4-yl-imidazo[1,5-A]pyridine derivatives
PL2155712T3 (pl) 3-(imidazolilo)-pirazolo[3,4-b]pirydyny
PL1889848T3 (pl) 6,7-nienasycona-7-karbamoilo-podstawiona pochodna morfinanu
IL241548A0 (en) Antibacterial quinoline derivatives
EP2202231A4 (en) 2,3-DIHYDROIMINOISOINDOLE DERIVATIVE
AP2322A (en) Antibacterial quinoline derivatives.
PL2099765T3 (pl) 5-, 6- lub 7-podstawione pochodne 3-aryloizochinolinoaminy jako środki przeciwnowotworowe
IL201444A0 (en) New 4, 8 - diphenyl - polyazanaphthalene derivatives
IL194972A0 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-
IL193483A0 (en) 4-amino-1,5-substituted 1,5 - dihydro - imidazol -2- ones
PT2010509E (pt) Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona como agentes de dilatação do canal de potássio
宋贺民 et al. 胶东大磨曲家金矿地球化学异常模式及找矿意义
卢会军 et al. 浅析配矿管理 3
王春宏 et al. 西藏崩纳藏布砂金矿中金的来源研究
牟振山 et al. 注浆胶结矿柱充填工艺在河西金矿的研究 3
高光 盲竖井井位选择的可行性研究
আবু জাফর মোহাম্মদ সালেহ et al. টেনিসনের ভাবনায় মৃত্যু প্রসঙ্গ
张华全 et al. 山东省乳山市西涝口金矿床地质特征及找矿方向
段晓华 甘肃马泉金矿成因类型探讨
江明阳 河台金矿高村矿床 11 号主矿体资源储量变化分析